Abstract: Roof structure (1) for a vehicle, wherein the roof structure (1) comprises a roof sky (2), wherein the roof sky comprises a foam or sandwich layer (3) and a surface layer (4) covering the foam or sandwich layer preferably to a vehicle interior and wherein a microphone unit (5) is arranged at the foam or sandwich layer (3), the microphone unit (5) comprises at least one mounting means (6), the foam or sandwich layer (3) comprises at least one recess (7) to receive the at least one mounting means (6) and the mounting means (6) of the microphone unit (5) in a mounted condition of the microphone unit (5) is arranged in the at least one recess (7) thereby holding the microphone unit (5) at the foam or sandwich layer (3).

Abstract: The present disclosure relates to compositions of oligonucleotide (e.g., SMAD7 antisense oligonucleotide diastereomers) and methods of manufacturing, assessing efficacy, and using the compositions.

Abstract: A microphone assembly for exterior use on vehicles having a housing base including at least one compartment, a PCBA (printed circuit board assembly) with at least one acoustic membrane, a sealing cover to at least partially overlap with the compartment is disclosed. The sealing cover has at least one opening with said opening at least partially aligned with said acoustic membrane. The assembly has a housing cover including a first grid at least partially aligned with said opening in the sealing cover, and a shielding cover. The shielding cover has a second grid at least partially aligned with said opening in the sealing cover. The first grid and the second grid are aligned in offset in order to provide a labyrinth path without straight passthrough passages from the exterior of the microphone assembly to the acoustic membrane.

Abstract: Roof structure (1) for a vehicle, wherein the roof structure (1) comprises a roof sky (2), wherein the roof sky comprises a foam or sandwich layer (3) and a surface layer (4) covering the foam or sandwich layer preferably to a vehicle interior and wherein a microphone unit (5) is arranged at the foam or sandwich layer (3), the microphone unit (5) comprises at least one mounting means (6), the foam or sandwich layer (3) comprises at least one recess (7) to receive the at least one mounting means (6) and the mounting means (6) of the microphone unit (5) in a mounted condition of the microphone unit (5) is arranged in the at least one recess (7) thereby holding the microphone unit (5) at the foam or sandwich layer (3).

Abstract: The present invention relates to methods of treating, preventing or managing intestinal fibrosis by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of intestinal fibrosis using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-? (TGF-?) levels, ?-Smooth Muscle Actin (a-SMA) levels, and/or phosphorylated Mothers Against Decapentaplegic Homolog 3 (p-SMAD3) levels.

Abstract: The present invention relates to methods of treating, preventing, and/or managing celiac disease by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of celiac disease using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-? (TGF-?) signaling activity.

Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.

Abstract: Described herein are methods of treating inflammatory bowel disease (IBD) in a patient having IBD using SMAD7 antisense oligonucleotides.

Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Abstract: Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.

Abstract: The present invention relates to treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) using antisense nucleotides that are directed against polymorphic forms (e.g., those containing single nucleotide polymorphisms) of the SMAD7 mRNA. The invention thus relates to treatment methods for subjects having polymorphic forms of SMAD7 and antisense oligonucleotides that specifically target SMAD7 mRNA transcripts containing polymorphisms.

Abstract: The present disclosure relates to compositions of Mothers Against Decapentaplegic Homolog 7 (SMAD7) antisense nucleotides and methods of using the composition in treating, preventing, and/or ameliorating a skin inflammation, e.g., psoriasis, or symptoms thereof.

Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.

Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Abstract: The present invention relates to treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) using antisense nucleotides that are directed against polymorphic forms (e.g., those containing single nucleotide polymorphisms) of the SMAD7 mRNA. The invention thus relates to treatment methods for subjects having polymorphic forms of SMAD7 and antisense oligonucleotides that specifically target SMAD7 mRNA transcripts containing polymorphisms.

Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.

Abstract: Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer.